L26/P-893 Investigating technical variability in trophectoderm biopsy: implications for PGT data quality, re-biopsy and live-birth
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von V. Casciani und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Which procedural and embryological factors of trophectoderm biopsy influence molecular data quality in PGT-A (median-absolute-pairwise-difference, MAPD-score), and do they associate with live-birth per euploid transfer? Summary answer Both day7-biopsy and biopsy operators were associated with higher MAPD-score. Only day7-biopsy was associated with higher no-result rates and lower live-birth per euploid transfer. What is known already PGT-A generates inconclusive results in 2–6% of trophectoderm-biopsies, mainly due to insufficient DNA or analytical noise. Transferring embryos without a conclusive PGT-A result (no-result) or performing rebiopsy is undesirable and introduces unwanted risk. Variability in biopsy technique (including lack of standardization, laser use, operator expertise) may affect genetics results. Objective metrics, including MAPD-score quantify genome-wide technical noise, with lower values indicating higher data reliability. However, the impact of these technical factors remains poorly characterized. Improved understanding is therefore essential to enhance quality control, troubleshooting strategies, and best practices in PGT-A. Study design, size, duration Retrospective single-center study including 695 trophectoderm biopsies for PGT-A (September-2024 and February-2025). Procedural (e.g., number of laser-shots, duration of the procedure, biopsy practictioner) and embryological variables (e.g., blastocyst quality and expansion grade, day of biopsy) were analyzed for associations with no-result rates and MAPD-scores. Among 334 vitrified euploid blastocysts, 152 were transferred after warming. All variables, including MAPD-score, were tested for associations with clinical outcomes up to live-birth. GEE were used for linerar/logistic regressions. Participants/materials, setting, methods Day 5–7 (defined through hours post-insemination) trophectoderm biopsies were performed using the pulling method. A double biopsy was conducted in 2% of cases. Blastocyst quality was assessed according to Gardner’s criteria. Expansion grade was classified as expanded (fully enclosed in the zona pellucida), in-hatching, or fully hatched. MAPD-score served as a quantitative marker of molecular data quality, ranging from 0.13 to 0.50 (median 0.16, Q1 0.15, Q3 0.17). Main results and the role of chance The overall no-result rate was 2.6% (N = 18/695), in 13 cases because of no DNA amplification, in 5 because of low molecular data quality or uncertain data interpretation. The only feature significantly associated with this outcome were day-7 biopsies, that exhibited a significantly higher no-result rate compared to days 5–6 (6.1% [N = 6/98] versus 2.0% [N = 12/597]; OR = 4.91, 95%CI:1.30–18.55, p = 0.019). This was largely due to higher no DNA amplications rates (0% in day5, 1.6% in day6 and 5.1% in day7), rather than to low molecular data quality in case of amplification. In fact, the MAPD-score decreased from day5 to 6 and 7 (median day-5: 0.165; day-6: 0.159; day-7: 0.1565; B = −0.011; p < 0.001). Also among the seven biopsy practitioners, significantly variable MAPD-scores were reported (median ranging 0.153–0.174; p < 0.001). Nevertheless, although the MAPD-score was higher in inconclusive (N = 5, median 0.3 Q1 0.15 Q3 0.48) versus conclusive results (N = 677, median 0.16 Q1 0.15 Q3 0.17), no significant association was reported with the no-result rate. Among transferred embryos, the live-birth rate was 48.0%. Neither the MAPD-score nor any other parameter under investigations showed associations with it. Also for this outcome, only day7 biopsies versus 5/6 remained the only features showing a significant negative association (OR = 0.293; 95%CI:0.125–0.690; p = 0.005). Limitations, reasons for caution Single center retrospective design limits generalizability. Sample size in no-result cases is still low. Residual confounding from unmeasured procedural or biological variables cannot be excluded. Wider implications of the findings These findings suggest that variability in MAPD-score reflects underlying differences in biopsy performance and should be considered a relevant quality-monitoring variable in PGT. MAPD-score may serve as a metric to support standard operating procedures definition and standardization. Larger datasets may further reveal significant associations with no-result rates. Trial registration number No
Zitieren
APA
Casciani, V., Cermisoni, G., Innocenti, F., Taggi, M., Stati, A., Capaldi, V., Chimienti, F., Albricci, L., Rienzi, L., Capalbo, A., Cimadomo, D., & Ottolini, C. (2026). L26/P-893 Investigating technical variability in trophectoderm biopsy: implications for PGT data quality, re-biopsy and live-birth. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1217
Vancouver
Casciani V, Cermisoni G, Innocenti F, Taggi M, Stati A, Capaldi V, et al. L26/P-893 Investigating technical variability in trophectoderm biopsy: implications for PGT data quality, re-biopsy and live-birth. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1217
BibTeX
@article{Casciani2026,
author = {Casciani, V. and Cermisoni, G.C. and Innocenti, F. and Taggi, M. and Stati, A. and Capaldi, V. and Chimienti, F. and Albricci, L. and Rienzi, L. and Capalbo, A. and Cimadomo, D. and Ottolini, C.S.},
title = {L26/P-893 Investigating technical variability in trophectoderm biopsy: implications for PGT data quality, re-biopsy and live-birth},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1217}
}
EUVIMED